SCHEMBL1301600

SCHEMBL1301600

COc1nc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2C(CO)C(C)(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METTL3 Q86U44 1/20 0.60
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
EGFR P00533 3/20 0.32
PLA2G4A P47712 2/20 0.32
THRB P10828 1/20 0.32
TSHR P16473 1/20 0.31
HIF1A Q16665 1/20 0.31
NOTUM Q6P988 1/20 0.31
CD38 P28907 1/20 0.31
PTPN1 P18031 1/20 0.31
CMA1 P23946 1/20 0.31
LMNA P02545 1/20 0.31
CYP2C9 P11712 1/20 0.31
ATP6V1B2 P21281 1/20 0.31
TBXA2R P21731 1/20 0.31
EDNRA P25101 1/20 0.31
TARBP2 Q15633 1/20 0.31
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1301597 1.00 METTL3 (0.60) METTL3TP53POLBRXFP1EGFR
SCHEMBL12108010 0.92 METTL3 (0.56) METTL3THRBTSHRHIF1ACD38
SCHEMBL1301007 0.92 METTL3 (0.54) METTL3TP53RXFP1EGFRTHRB
SCHEMBL1301011 0.92 METTL3 (0.54) METTL3TP53RXFP1EGFRTHRB
SCHEMBL1301404 0.92 METTL3 (0.54) METTL3EGFR
SCHEMBL1301401 0.92 METTL3 (0.54) METTL3EGFR
SCHEMBL1301430 0.92 METTL3 (0.54) METTL3EGFRTHRBTSHRHIF1A
SCHEMBL1301433 0.92 METTL3 (0.54) METTL3EGFRTHRBTSHRHIF1A
SCHEMBL12108019 0.91 METTL3 (0.54) METTL3EGFRPLA2G4ALMNA
SCHEMBL12108004 0.91 METTL3 (0.54) METTL3EGFRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 US claimed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 US claimed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885TP53 3051/4885POLB 10/4885
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885TP53 3051/4885POLB 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.